Back to Search
SAL HALABI, PHARM.D.
PHARM.D.
Pharmacist
NPI: 1225314057Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
055639(NY)
Research & Publications (20)
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
PMID 19633053·Ann Oncol·2010
8-other
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
PMID 19589569·Urology·2010
8-other
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
PMID 18574490·Prostate Cancer Prostatic Dis·2009
8-other
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
PMID 19380448·J Clin Oncol·2009
8-other
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
PMID 19211452·J Natl Cancer Inst·2009
1-meta
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
PMID 19168670·Ann Oncol·2009
3-trial
Second-line chemotherapy for advanced hormone-refractory prostate cancer.
PMID 18347563·Clin Adv Hematol Oncol·2008
6-review
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
PMID 18407435·Int J Radiat Oncol Biol Phys·2008
3-trial
Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans.
PMID 18945689·Am J Epidemiol·2008
8-other
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.
PMID 18037582·Int J Radiat Oncol Biol Phys·2008
3-trial
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
PMID 18487572·J Clin Oncol·2008
4-observational
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.
PMID 18349276·Cancer Epidemiol Biomarkers Prev·2008
8-other
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
PMID 18272914·Ann Oncol·2008
3-trial
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PMID 18309951·J Clin Oncol·2008
6-review
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
PMID 18291508·Urology·2008
3-trial
Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.
PMID 18303003·Am J Epidemiol·2008
8-other
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
PMID 18824434·Clin Genitourin Cancer·2008
3-trial
Circulating levels of inflammatory cytokines and risk of colorectal adenomas.
PMID 18172326·Cancer Res·2008
8-other
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
PMID 18936475·J Clin Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 291 AVENUE W
BROOKLYN, NY 11223 - Phone
- (646) 552-4158
Quick Facts
- NPI
- 1225314057
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile